Senior Director, New Ventures and Investments, Monash University
| Role | Organisation | Sources |
|---|---|---|
| Director | George Medicines | Brandon BioCatalyst portfolio, Brandon Capital portfolio |
| Senior Director | Monash Ventures Pre-Seed Fund | - |
| Senior Director, New Ventures and Investments | Monash University | - |
| Senior Investment Manager (former) | Brandon Capital | Brandon BioCatalyst portfolio, Brandon Capital portfolio, Startup Daily |
Stories naming Dr Ingmar Wahlqvist. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
xCystence Bio secured pre-seed funding from Uniseed, Monash Ventures, Breakthrough Victoria, and BioCurate to develop targeted protein degraders for treating genetic kidney disease.
FytonBio secured one million dollars in pre-seed funding from Breakthrough Victoria and Monash University to develop antibody therapies for autoimmune diseases using Monash's GREAT platform.
Melbourne wearable drug-delivery startup Remagine Labs secured $500,000 pre-seed funding, split between Breakthrough Victoria and Monash University, to advance chronic condition treatment devices.
The George Institute's commercial arm and its drug development company have secured $53 million from three Australian investors to speed commercialisation of medical research, with Brandon Capital's Ingmar Wahlqvist involved.